Recently, in a randomized, placebo-controlled, double-blind, parallel-group phase 2 trial [36] enrolling statin-treated patients with hypertriglyceridemia, it was observed that a novel second-generation PPARα agonist (pemafibrate) is effective, safe, and well-tolerated for the reduction of TG, and also for the reduction of apoB48, apoCIII, and remnant cholesterol concentrations. Here, APOC3 is linked to hypertriglyceridemia.